Related Experiment Video

Updated: Jun 16, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

[Which aldosterone antagonist? Choosing between sprionolactone and the novel drug finerenone]

Kang He Zheng1,2, Camiel L M de Roij van Zuijdewijn3, Loek van Heerebeek1

  • 1OLVG, afd. Cardiologie, Amsterdam.

Nederlands Tijdschrift Voor Geneeskunde
|June 15, 2026
PubMed
Abstract

Insights

Finerenone effectively reduces kidney and cardiovascular events in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). This review guides mineralocorticoid receptor antagonist (MRA) selection for cardiovascular-kidney-metabolic syndrome.

Area of Science:

  • Cardiology
  • Nephrology
  • Endocrinology

Background:

  • Patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) face elevated cardiovascular risks.
  • Mineralocorticoid receptor overactivation contributes to cardiac and renal inflammation and fibrosis.

Purpose of the Study:

  • Review clinical evidence for mineralocorticoid receptor antagonists (MRAs).
  • Provide guidance on selecting MRAs for cardiovascular-kidney-metabolic syndrome.

Main Methods:

  • Literature review of clinical trials and outcome studies.
  • Analysis of MRA efficacy and safety data.

Main Results:

  • Finerenone demonstrated significant reductions in kidney and cardiovascular events in T2DM patients (FIDELIO-DKD, FIGARO-DKD).
  • Combination therapy with finerenone and empagliflozin reduced proteinuria (CONFIDENCE trial).
  • Finerenone showed cardiovascular benefits in heart failure with preserved ejection fraction (HFpEF) (FINEARTS-HF).

Conclusions:

  • Finerenone is proven effective for CKD and T2DM.
  • Steroidal MRAs remain important for treatment-resistant hypertension.
  • Patient factors like blood pressure and hyperkalemia risk guide MRA choice.

More Related Videos

A Novel Method: Super-selective Adrenal Venous Sampling06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...